Escitalopram
Lexapro (escitalopram) is a small molecule pharmaceutical. Escitalopram was first approved as Lexapro on 2002-08-14. It is used to treat major depressive disorder in the USA. The pharmaceutical is active against sodium-dependent serotonin transporter.
Download report
Favorite
Top Prescription Drugs
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| mental disorders | D001523 |
Trade Name
FDA
EMA
Lexapro (generic drugs available since 2012-03-14)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Escitalopram oxalate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| LEXAPRO | AbbVie | N-021323 RX | 2002-08-14 | 3 products, RLD, RS |
Show 1 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| escitalopram | ANDA | 2023-06-01 |
| lexapro | New Drug Application | 2021-09-20 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| major depressive disorder | EFO_0003761 | D003865 | F22 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
514 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Major depressive disorder | D003865 | EFO_0003761 | F22 | 11 | 24 | 30 | 51 | 20 | 129 |
| Depression | D003863 | F33.9 | 5 | 16 | 19 | 50 | 35 | 117 | |
| Healthy volunteers/patients | — | 24 | — | — | 4 | 4 | 32 | ||
| Anxiety disorders | D001008 | EFO_0006788 | F41.1 | 3 | 2 | 6 | 8 | 4 | 22 |
| Depressive disorder | D003866 | EFO_1002014 | F32.A | 4 | 1 | 6 | 2 | 3 | 15 |
| Anxiety | D001007 | EFO_0005230 | F41.1 | — | 1 | 3 | 5 | 6 | 14 |
| Schizophrenia | D012559 | EFO_0000692 | F20 | — | — | 2 | 8 | 1 | 11 |
| Alzheimer disease | D000544 | EFO_0000249 | F03 | 1 | 1 | 3 | 4 | 2 | 10 |
| Bipolar disorder | D001714 | EFO_0000289 | F30.9 | 1 | 2 | 3 | 2 | 2 | 9 |
| Obsessive-compulsive disorder | D009771 | EFO_0004242 | F42 | — | — | 1 | 6 | 1 | 8 |
Show 47 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Treatment-resistant depressive disorder | D061218 | 1 | — | 7 | — | 1 | 9 | ||
| Neoplasms | D009369 | C80 | 1 | 1 | 4 | — | 1 | 7 | |
| Cocaine-related disorders | D019970 | F14 | 1 | 5 | 1 | — | — | 6 | |
| Mood disorders | D019964 | EFO_0004247 | F30-F39 | — | 1 | 1 | — | 2 | 4 |
| Parkinson disease | D010300 | EFO_0002508 | G20 | — | 2 | 2 | — | 1 | 4 |
| Hot flashes | D019584 | — | — | 1 | — | 3 | 4 | ||
| Breast neoplasms | D001943 | EFO_0003869 | C50 | — | 1 | 1 | — | 1 | 3 |
| Opioid-related disorders | D009293 | EFO_0005611 | F11 | — | 1 | 1 | — | — | 2 |
| Hiv infections | D015658 | EFO_0000764 | B20 | — | — | 2 | — | — | 2 |
| Fibromyalgia | D005356 | EFO_0005687 | M79.1 | — | 1 | 1 | — | 1 | 2 |
Show 24 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Menopause | D008593 | EFO_0003922 | N95 | — | 1 | — | — | 1 | 2 |
| Ischemic stroke | D000083242 | 1 | 2 | — | — | — | 2 | ||
| Male infertility | D007248 | EFO_0004248 | N46 | — | 1 | — | — | — | 1 |
| Chronic hepatitis c | D019698 | EFO_0004220 | B18.2 | — | 1 | — | — | — | 1 |
| Aphasia | D001037 | HP_0002381 | R47.01 | — | 1 | — | — | — | 1 |
| Glioma | D005910 | EFO_0000520 | — | 1 | — | — | — | 1 | |
| Chronic kidney failure | D007676 | EFO_0003884 | N18.6 | — | 1 | — | — | — | 1 |
| Bereavement | D001601 | — | 1 | — | — | — | 1 | ||
| Attention deficit disorder with hyperactivity | D001289 | EFO_0003888 | F90 | — | 1 | — | — | — | 1 |
| Neurodevelopmental disorders | D065886 | F89 | — | 1 | — | — | — | 1 |
Show 6 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Spinal cord injuries | D013119 | EFO_1001919 | 2 | — | — | — | 1 | 3 | |
| Substance-related disorders | D019966 | EFO_0003890 | F13 | 1 | — | — | — | 1 | 2 |
| Autism spectrum disorder | D000067877 | F84.0 | 1 | — | — | — | 1 | 2 | |
| Stress urinary incontinence | D014550 | HP_0010992 | 1 | — | — | — | — | 1 | |
| Fecal incontinence | D005242 | R15 | 1 | — | — | — | — | 1 | |
| Hepacivirus | D016174 | 1 | — | — | — | — | 1 | ||
| Premature ejaculation | D061686 | HP_0012876 | F52.4 | 1 | — | — | — | — | 1 |
| Respiratory insufficiency | D012131 | HP_0002093 | J96.9 | 1 | — | — | — | — | 1 |
| Hypercapnia | D006935 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Cardiovascular diseases | D002318 | EFO_0000319 | I98 | — | — | — | — | 4 | 4 |
| Pharmacokinetics | D010599 | — | — | — | — | 2 | 2 | ||
| Cognition | D003071 | EFO_0003925 | — | — | — | — | 2 | 2 | |
| Perimenopause | D047648 | — | — | — | — | 1 | 1 | ||
| Pregnancy | D011247 | EFO_0002950 | Z33.1 | — | — | — | — | 1 | 1 |
| Wounds and injuries | D014947 | T14.8 | — | — | — | — | 1 | 1 | |
| Chronic disease | D002908 | — | — | — | — | 1 | 1 | ||
| Brain injuries | D001930 | S06.9 | — | — | — | — | 1 | 1 | |
| Alcohol-related disorders | D019973 | F10 | — | — | — | — | 1 | 1 | |
| Suicidal ideation | D059020 | EFO_0004320 | R45.851 | — | — | — | — | 1 | 1 |
Show 19 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | ESCITALOPRAM |
| INN | escitalopram |
| Description | Escitalopram is a 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile that has S-configuration at the chiral centre. It is the active enantiomer of citalopram. It has a role as an antidepressant and an EC 3.4.21.26 (prolyl oligopeptidase) inhibitor. It is a conjugate base of an escitalopram(1+). It is an enantiomer of a (R)-citalopram. |
| Classification | Small molecule |
| Drug class | Selective serotonin reuptake inhibitor (SSRI) |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | CN(C)CCC[C@@]1(c2ccc(F)cc2)OCc2cc(C#N)ccc21 |
Identifiers
| PDB | 5I71 |
| CAS-ID | 128196-01-0 |
| RxCUI | 321988 |
| ChEMBL ID | CHEMBL1508 |
| ChEBI ID | 36791 |
| PubChem CID | 146570 |
| DrugBank | DB01175 |
| UNII ID | 4O4S742ANY (ChemIDplus, GSRS) |
Target
Agency Approved
SLC6A4
SLC6A4
Organism
Homo sapiens
Gene name
SLC6A4
Gene synonyms
HTT, SERT
NCBI Gene ID
Protein name
sodium-dependent serotonin transporter
Protein synonyms
5-hydroxytryptamine (serotonin) transporter, 5HT transporter, 5HTT, Na+/Cl- dependent serotonin transporter, serotonin transporter 1, solute carrier family 6 (neurotransmitter transporter), member 4, solute carrier family 6 (neurotransmitter transporter, serotonin), member 4, Solute carrier family 6 member 4
Uniprot ID
Mouse ortholog
Slc6a4 (15567)
sodium-dependent serotonin transporter (Q60857)
Alternate
No data
Variants
Clinical Variant
Identifier | Target mutation | Effect | Evaluation | Status |
|---|---|---|---|---|
| VCV000638805 | CYP2C19, Gly91Arg | drug response | 2019-06-17 | P |
| VCV000638804 | CYP2C19, His78Tyr | drug response | 2019-06-17 | P |
| VCV000638803 | CYP2C19, Arg73Cys | drug response | 2019-06-17 | P |
| VCV000638802 | CYP2C19, Arg442Cys | drug response | 2019-06-17 | P |
| VCV000638801 | CYP2C19, Ser51Gly | drug response | 2019-06-17 | P |
| VCV000638800 | CYP2C19, Asp256Asn | drug response | 2019-06-17 | P |
| VCV000638799 | CYP2C19, Ile19Leu | drug response | 2019-06-17 | P |
| VCV000638798 | CYP2C19, Lys399=, Arg335Gln | drug response | 2019-06-17 | P |
| VCV000638797 | CYP2C19, Pro227= | drug response | 2019-06-17 | P |
| VCV000638796 | CYP2C19, Arg410Cys | drug response | 2019-06-17 | P |
Show 585 more
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 13,623 documents
View more details
Safety
Black-box Warning
Black-box warning for: Escitalopram, Lexapro
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
24,247 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more